



Increase of number of shares and votes in Vicore Pharma

Gothenburg, November 29, 2019 – Vicore Pharma Holding AB (publ)'s ("Vicore Pharma", or the "Company") registered share capital and number of outstanding shares and votes have increased during the month of November 2019.

As previously announced, the Company's board of directors resolved on November 13, 2019, by virtue of the authorization by the annual general meeting held on May 15, 2019, on a directed share issue of 7,800,000 new shares at a subscription price of SEK 16 per share. Through the share issue, Vicore Pharma received issue proceeds of approximately SEK 125 million before issue costs.

As of today, the total number of registered and outstanding shares and votes of Vicore Pharma amounts to 50,174,714. Furthermore, the registered share capital amounts to SEK 25,087,356.756435.

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com

Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 29 November 2019 at 08:00 CET.

About Vicore Pharma Holding AB (publ)

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs, VP01 and VP02.

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis ("IPF") and systemic sclerosis ("SSc"). VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an "IMiD"). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which has a significant high unmet need. The VP01 Phase IIa studies in IPF and SSc patients are expected to be initiated during the second half of 2019. VP02 is entering a phase of optimization of formulation before local tolerability studies will commence. The first clinical studies with VP02 are expected to start in 2020.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.